VA
AZN icon

Vident Advisory’s AstraZeneca AZN Stock Holding History

Vident Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8M Buy
51,702
+23,670
+84% +$4.45M 0.07% 239
2026
Q1 		$5.53M Buy
28,032
+3,236
+13% +$624K 0.05% 330
2025
Q4 		$4.56M Sell
24,796
-901
-4% -$158K 0.04% 353
2025
Q3 		$3.94M Buy
25,697
+598
+2% +$90.5K 0.04% 367
2025
Q2 		$3.51M Sell
25,099
-23,491
-48% -$3.29M 0.04% 356
2025
Q1 		$7.14M Buy
48,590
+31,800
+189% +$4.6M 0.1% 181
2024
Q4 		$2.2M Sell
16,790
-760
-4% -$106K 0.04% 390
2024
Q3 		$2.73M Buy
17,550
+2,582
+17% +$417K 0.07% 311
2024
Q2 		$2.33M Buy
14,968
+4,206
+39% +$633K 0.06% 316
2024
Q1 		$1.46M Sell
10,762
-315
-3% -$41.7K 0.03% 468
2023
Q4 		$1.49M Buy
11,077
+224
+2% +$29.1K 0.04% 454
2023
Q3 		$1.47M Buy
+10,853
New +$1.48M 0.05% 401

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vident Advisory's AZN Position: Q2 2026 in Review

Vident Advisory increased its AstraZeneca (AZN) stake by 84% in Q2 2026, buying an estimated $4.45M and bringing the position to 51,702 shares worth $9.8M. The position accounts for 0.07% of the portfolio, ranked #239.

Vident Advisory first reported a position in AZN in Q3 2023 and has held it in 12 quarters since. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Vident Advisory held 51,702 shares of AstraZeneca worth $9.8M as of Q2 2026.
  • Vident Advisory bought 23,670 AstraZeneca shares in Q2 2026, an estimated $4.45M.
  • AstraZeneca made up 0.07% of Vident Advisory's portfolio in Q2 2026, its #239 holding.
  • Vident Advisory first reported a position in AstraZeneca in Q3 2023 and has held it in 12 quarters since.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.